EICHOR
● Recruiting
Comparison of Sequential to Initial Combination Therapy in PAH
Condition: Pulmonary Arterial Hypertension (PAH) · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
About this study
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.
This description comes directly from the study's public registry record.
Talk to the study team
Zongye Cai, MD, PhD · +8618258236820 · z.cai@zju.edu.cn
Zexin Chen · +86 15867136069 · chenzexin@zju.edu.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06968962